Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
14 participants
INTERVENTIONAL
2012-10-31
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study hypothesis: Intralesional therapy with the calcium antagonist verapamil has equal treatment efficacy as steroid injection.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Intralesional Triamcinolone Versus Verapamil for Keloid Treatment
NCT06897969
Comparison of Recurrence Rate of Keloid After Excision Between Intra-operative Steroid Injection and Steroid With Platelet-rich Plasma Injection Combination Therapy
NCT06965088
Prevention of Hypertrophic Scars or Keloids
NCT00849004
Study to Evaluate Fractional Collagen Synthesis Within Keloid Scars and Identify Biomarkers of Keloid Scars
NCT01978301
The Effectiveness of Intralesional Botulinum Toxin A and Triamcinolone Acetonide Injections in Keloid Treatment
NCT06814288
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Verapamil
Verapamil 2.5 mg/mL injection sc intralesionally
Verapamil
Kenalog 10
Kenalog 10 mg/mL injection sc intralesionally
Kenalog 10
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Verapamil
Kenalog 10
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient 18 years old or greater
* Length of excisional scar after surgical removal of keloid between 2 and 10 cm
Exclusion Criteria
* Pregnancy or lactation
* Dementia
* Any heart or pulmonary condition
* Systemic treatment with beta-blockers, ACE-inhibitors or calcium antagonists
* Systemic corticosteroidal therapy
* Intralesional steroid treatment within 2 months of surgery to remove keloid
* Flap surgery
* Lesions to face, hands and other cosmetically sensitive areas
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of Western Australia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fiona M. Wood
Prof. Wood
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fiona M Wood, Professor
Role: PRINCIPAL_INVESTIGATOR
The University of Western Australia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Perth Hospital
Perth, Western Australia, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EC 067/2012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.